<DOC>
	<DOCNO>NCT01283061</DOCNO>
	<brief_summary>The objective study compare relative bioavailability zafirlukast tablets 20 mg 'ACCOLATEÂ® ' tablet 20 mg ( zafirlukast tablet 20 mg ) healthy , adult , human , subject fast condition monitor safety subject .</brief_summary>
	<brief_title>Bioequivalence Study Zafirlukast Tablets 20 mg Dr. Reddy 's Laboratories Limited Under Fasting Condition</brief_title>
	<detailed_description>open label , randomize , two-period , two treatment , two sequence , crossover , balance single dose comparative oral bioavailability study healthy , adult , human subject fast conditions.44 healthy , adult , human subjects.There 11-day interval treatment .</detailed_description>
	<mesh_term>Zafirlukast</mesh_term>
	<criteria>1 . The subject healthy human 18 45 year . 2 . The subject screen within 21 day prior administration first dose study drug . 3 . The subject BMI 18.5 24.9 weight kg/ height2 meter . 4 . The subject able communicate effectively study personnel . 5 . The subject able give write informed consent participate study . If subject female volunteer 6 . Is child bear potential practicing acceptable method birth control duration study judge investigator ( ) , condom , foam , jelly , diaphragm , intrauterine device ( IUD ) , abstinence . 7 . Is postmenopausal least 1 year . 8 . Is surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy perform subject ) . 1 . The subject history allergic response zafirlukast related drug . 2 . The subject use enzymemodifying drug within 30 day prior receive first dose study medication . 3 . The subject history drug dependence , recent history alcoholism moderate alcohol us . 4 . The subject significant disease clinically significant abnormal finding screen , medical history , physical examination , laboratory evaluation , ECG Xray recording . 5 . The subject disease condition might compromise haemopoietic , gastrointestinal , renal , hepatic , cardiovascular , respiratory , central nervous system , diabetes , psychosis body system . 6 . The subject history presence bronchial asthma 7 . The subject smoker smoke equal 10 cigarette per day equal 20 biddy per day refrain smoke study period . 8 . The subject history difficulty donate blood difficulty accessibility vein . 9 . The subject donate 1 unit ( 350 ml / 450 ml ) blood within 90 day prior receive first dose study medication . 10 . The subject positive hepatitis screen ( include subtypes A , B , C E ) 11 . The subject positive test result HIV antibody / syphilis ( RPR/VDRL ) . 12 . The subject receive investigational product , participated drug research study within period 90 day prior first dose study medication administration . 13 . Female volunteer demonstrate positive pregnancy screen . 14 . Female volunteer currently breastfeed . 15 . Female volunteer willing use contraception study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>